{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:54:34Z","timestamp":1777866874628,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Improved maintenance treatments are needed for patients with relapsed\/refractory aggressive lymphomas after autologous haematopoietic stem cell transplantation (ASCT). Several studies with lenalidomide have been found to have activity in the treatment of relapsed\/refractory aggressive lymphomas. In the present phase I\/II, single\u2010arm, open\u2010label study, 59 patients with high\u2010risk relapsed non\u2010Hodgkin lymphoma received pretransplant BEAM chemotherapy and ASCT followed by 12\u2009months of maintenance lenalidomide once daily on Days 1\u201321 (28\u2010day\u2009cycles) beginning at post\u2010transplantation Day 100. The most common histologies were mantle cell lymphoma (56%) and diffuse large B\u2010cell lymphoma (24%). The maximum tolerated dose in the dose\u2010finding part of the study was 15\u2009mg, but cytopenias led to the subsequent adoption of a 10\u2009mg dose in the final study. Sixteen patients (27%) completed 12\u2009cycles of lenalidomide maintenance. The most common reason for discontinuation was adverse events (31%). These were primarily haematologic, and 56% of patients experienced Grade 3\u20134 events. Two\u2010year PFS rates (95% CIs) were 70% (56%\u201380%), 45% (19%\u201368%) and 81% (66%\u201390%); 2\u2010year OS rates (95% CIs) were 91% (80%\u201396%), 93% (61%\u201399%) and 90% (76%\u201396%) in all patients, patients completing and patients not completing 12\u2010month maintenance respectively. These results do not support the use of lenalidomide maintenance in this setting.<\/jats:p>","DOI":"10.1111\/bjh.18821","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T12:11:18Z","timestamp":1682424678000},"page":"116-121","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lenalidomide maintenance following high\u2010dose therapy and autologous haematopoietic stem cell transplantation in chemo\u2010resistant or high\u2010risk non\u2010<scp>H<\/scp>odgkin lymphoma: A phase I\/<scp>II<\/scp> study"],"prefix":"10.1111","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"University of Kansas Cancer Center  Westwood Kansas USA"},{"name":"Houston Methodist Hospital and Neal Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Bierman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Gregory","family":"Bociek","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Lyden","sequence":"additional","affiliation":[{"name":"College of Public Health University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Meza","sequence":"additional","affiliation":[{"name":"College of Public Health University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"University Hospital Seidman Cancer Center, Case Western Reserve University  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70030-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.014"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.213"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04203.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.004"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716652861"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0537-5"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12449"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4639.4639"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30358-6"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30067-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12846"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T10:31:30Z","timestamp":1699612290000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/bjh.18821"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18821","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"2023-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}